期刊文献+

替莫唑胺在侵袭性垂体瘤及垂体腺癌中的治疗进展 被引量:1

Advances in the Treatment of Temozolomide in Aggressive Pituitary Tumors and Pituitary Adenocarcinoma
原文传递
导出
摘要 替莫唑胺(TMZ)是一种口服二代咪唑并四嗪类具有抗肿瘤活性的烷化剂,通过对DNA鸟嘌呤的甲基化来干扰基因转录而诱导DNA损伤,目前是治疗恶性胶质瘤的一线化疗药物。最近有关于TMZ治疗侵袭性垂体腺瘤及垂体癌的报道,有效率分别为60%和69%,且未发生明显并发症。O6-甲基鸟嘌呤-DNA转移酶(MGMT)的表达水平与其疗效呈负相关,从而可能干扰其疗效,由于目前缺乏对垂体癌及侵袭性垂体瘤的有效治疗手段,所以不应否认TMZ对此类患者的治疗有效性。TMZ对侵袭性垂体瘤及垂体癌的治疗机制及有效性仍需进一步探索。 Temozolomide(TMZ) is an oral second-generation imidazole and tetrazine with anti-tumor activity of alkylating agents.It interferes with gene transcription and DNA damage induced by methylation of DNA guanine.It is currently the first-line chemotherapy drugs treatment of malignant glioma.Recently,the TMZ treatment of invasive pituitary adenomas and pituitary cancer have been reported,and the efficiency respectively achieve 60% and 69% with no obvious complications occured.O6-methylguanine-DNA transferase(MGMT) expression levels and its efficacy is negatively correlated,which may interfere with its efficacy.Since the lack of an effective treatment for pituitary cancer and invasive pituitary adenoma at present,So TMZ effectiveness of the treatment of such patients should not be denied.TMZ on the mechanisms and effectiveness of the treatment of invasive pituitary adenoma and pituitary carcinoma requires further exploration.
作者 谢民 丁永忠
出处 《现代生物医学进展》 CAS 2013年第17期3394-3396,3385,共4页 Progress in Modern Biomedicine
关键词 替莫唑胺 侵袭性垂体瘤 垂体腺癌 MGMT Temozolomide Aggressive pituitary tumors Pituitary adenocarcinoma MGMT
  • 相关文献

参考文献36

  • 1Feman dez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)[J]. Clinical Endocrinology,2010,72(3):377-382.
  • 2Dudziak K, Honegger J, Bomemann A, et al. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course: case report and review of the literature [J]. Journal of Clinical Endocrinology & Metabolism,2011,96(9):2665-2669.
  • 3Colao A, Ochoa AS, Auriemma RS, et al. Pituitary carcinomas [J]. Front Horm Res,2010,38:94-108.
  • 4Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma[J]. Lancet Oneol,2006,7(6):518-520.
  • 5Meij BP,Lopes MB, Ellegala DB, et al. The long-term significance of microscopic dural invasion m 354 patients with pituitary adenomas treated with transsphenoidal surgery[J]. J Neurosurg,2002,96(2): 196- 208.
  • 6Korbonits M,Carlsen E. Recent clinical and pathophysiologi-cal advances in non functioning pituitary adenomas[J]. Horm Res,2009,71 (2): 123-130.
  • 7Lloyd RV, Kovacs K, Young WF, et al. Pituitary turnouts:introduction. In: Tumors of the pituitary gland, DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): World Health Organization Classification of tumours. Pathology and Genetics Tumours of Endocrine Organs [M]. IARC Press: Lyon,2004:26-29.
  • 8Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications [J]. Journal of Neurosurgery,2011,114(2):336-344.
  • 9Raverot G, Wierinckx A, Dantony E, et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up [J]. Journal of Clinical Endocrinology and Metabolism,2010,95 (4): 1708- 1716.
  • 10Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas[J]. Neurosurgery,2006,59(2):255-266.

同被引文献15

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部